Deutsch English Français

Contact

EP1417351

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1417351

EP1417351 - ANTISENSE MODULATION OF APOLIPOPROTEIN(A) EXPRESSION [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 15.04.2011 Database last updated on 13.11.2024
Most recent event Tooltip	15.04.2011	Application deemed to be withdrawn	published on 18.05.2011 [2011/20]
Applicant(s)	For all designated states Isis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 / US
	[N/P]
Former [2005/26]	For all designated states Isis Pharmaceuticals, Inc. 1896 Rutherford Road Carlsbad, CA 92008 / US
Former [2004/20]	For all designated states ISIS PHARMACEUTICALS, INC. 2292 Faraday Avenue Carlsbad, CA 92008 / US
Inventor(s)	01 / CROOKE, Rosanne, M. 3211 Piraqua Street Carlsbad, CA 92009 / US
	02 / GRAHAM, Mark, J. 2305 S. Ola Vista San Clemente, CA 92672 / US
	[2004/20]
Representative(s)	Hallybone, Huw George, et al Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[N/P]
Former [2008/29]	Hallybone, Huw George, et al Carpmaels & Ransford 43-45 Bloomsbury Square London WC1A 2RA / GB
Former [2006/21]	Manaton, Ross Timothy, et al Bromhead Johnson, Kingsbourne House, 229-231 High Holborn London WC1V 7DP / GB
Former [2004/23]	Hale, Stephen Geoffrey, et al Bromhead Johnson, Kingsbourne House, 229-231 High Holborn London WC1V 7DP / GB
Former [2004/20]	Hale, Stephen Geoffrey JY & GW Johnson, Kingsbourne House, 229-231 High Holborn London WC1V 7DP / GB
Application number, filing date	02794670.6	05.08.2002
	[2004/20]
	WO2002US24920
Priority number, date	US20010923515	07.08.2001 Original published format: US 923515
	[2004/20]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO03014307
	Date:	20.02.2003
	Language:	EN
	[2003/08]
	Type:	A2 Application without search report
	No.:	EP1417351
	Date:	12.05.2004
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 20.02.2003 takes the place of the publication of the European patent application.
	[2004/20]
Search report(s)	International search report - published on:	US	23.10.2003
	(Supplementary) European search report - dispatched on:	EP	08.04.2005
Classification	IPC:	C12Q1/68, A01N41/04, C07H21/04, A61K31/07	[2004/20]
	CPC:	C12N15/113 (EP,US); A61P3/06 (EP); A61P9/00 (EP); A61P9/10 (EP); A61K38/00 (EP,US); C12N2310/315 (EP,US); (+) C12N2310/321 (EP,US); C12N2310/3341 (EP,US); C12N2310/341 (EP,US); C12N2310/346 (EP,US); Y02P20/582 (EP,US) (-)
	C-Set:	C12N2310/321, C12N2310/3525 (EP,US)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR [2004/20]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
	RO	Not yet paid
	SI	Not yet paid
Title	German:	ANTISENSE-MODULATION DER EXPRESSION VON APOLIPOPROTEIN(A)	[2004/20]
	English:	ANTISENSE MODULATION OF APOLIPOPROTEIN(A) EXPRESSION	[2004/20]
	French:	MODULATION ANTISENS DE L'EXPRESSION DE L'APOLIPOPROTEINE (A)	[2004/20]
Entry into regional phase	01.03.2004	National basic fee paid
	01.03.2004	Search fee paid
	01.03.2004	Designation fee(s) paid
	01.03.2004	Examination fee paid
Examination procedure	03.03.2003	Request for preliminary examination filed International Preliminary Examining Authority: US
	16.02.2004	Amendment by applicant (claims and/or description)
	01.03.2004	Examination requested [2004/20]
	21.02.2006	Despatch of a communication from the examining division (Time limit: M06)
	28.08.2006	Reply to a communication from the examining division
	18.01.2007	Despatch of a communication from the examining division (Time limit: M06)
	30.07.2007	Reply to a communication from the examining division
	09.05.2008	Despatch of a communication from the examining division (Time limit: M06)
	19.11.2008	Reply to a communication from the examining division
	23.06.2009	Despatch of a communication from the examining division (Time limit: M06)
	18.12.2009	Reply to a communication from the examining division
	15.07.2010	Communication of intention to grant the patent
	26.11.2010	Application deemed to be withdrawn, date of legal effect [2011/20]
	30.12.2010	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2011/20]
Divisional application(s)	EP10175588.2 / EP2272985
	EP10175604.7 / EP2316968
Fees paid	Renewal fee
	01.03.2004	Renewal fee patent year 03
	08.08.2005	Renewal fee patent year 04
	07.08.2006	Renewal fee patent year 05
	03.08.2007	Renewal fee patent year 06
	20.08.2008	Renewal fee patent year 07
	07.08.2009	Renewal fee patent year 08
	06.08.2010	Renewal fee patent year 09
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]US5721138 (LAWN RICHARD MARK [US]) [X] 1-21 * column 6, line 65 - column 7, line 11 *;
		[A]US5866551 (BENOIT PATRICK [FR], et al) [A] 1-21* column 3, line 34 - line 45 *;
		[X]WO9935241 (RHONE POULENC RORER PHARMA [US], et al) [X] 1,2 * page 23, line 11 - line 32; example 3 *
	International search	[X]WO9609392 (RIBOZYME PHARM INC [US]);
		[Y]US5801154 (BARACCHINI EDGARDO [US], et al);
		[A] - KOSTNER ET AL., "Lipoprotein (a): still an enigma?", CURRENT OPINION IN LIPIDOLOGY, (2002), vol. 13, pages 391 - 396, XP002965341 DOI: http://dx.doi.org/10.1097/00041433-200208000-00006
		[A] - JEN ET AL., "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies", STEM CELLS, (2000), vol. 18, pages 307 - 319, XP002948605 DOI: http://dx.doi.org/10.1634/stemcells.18-5-307
		[A] - BRANCH A., "A good antisense molecule is hard to find", TIBS, (199802), vol. 23, pages 45 - 50, XP002917429 DOI: http://dx.doi.org/10.1016/S0968-0004(97)01155-9
		[Y] - MCLEAN ET AL., "cDNA sequence of human apolipoprotein (a) is homologous to plasminogen", NATURE, (1987), vol. 330, pages 132 - 137, XP002965342 DOI: http://dx.doi.org/10.1038/330132a0
		[Y] - WEINTRAUB H.M., "Antisense RNA and DNA", SCIENTIFIC AMERICAN, (199001), pages 40 - 46, XP002965343
		[Y] - MILLIGAN ET AL., "Current concepts in antisense drug design", MEDICINAL CHEMISTRY, (1993), vol. 36, no. 14, pages 1923 - 1937, XP002913877 DOI: http://dx.doi.org/10.1021/jm00066a001
		[Y] - FRITZ ET AL., "Cationic polystyrene nanoparticles: preparation and characterization of a model drug carrier system for antisense oligonucleotides", JOURNAL OF COLLOID AND INTERFACE SCIENCE, (1997), vol. 195, pages 272 - 288, XP002961842 DOI: http://dx.doi.org/10.1006/jcis.1997.5172
		[X] - FRANK ET AL., "Adenovirus-mediated apo(a) antisense RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo", GENE THERAPY, (2001), vol. 8, pages 425 - 430, XP002965344 DOI: http://dx.doi.org/10.1038/sj.gt.3301434
		[X] - MORISHITA ET AL., "Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apo(a) selectively inhibit apo(a) but not plasminogen gene expression", CIRCULATION, (1998), vol. 98, pages 1898 - 1904, XP002965345
	by applicant	- SANGHVI, NUCLEIC ACIDS RESEARCH, (1993), vol. 21, pages 3197 - 3203

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p